Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antiviral Agents* / therapeutic use
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Newborn, Diseases* / drug therapy
  • Infant, Newborn, Diseases* / prevention & control
  • Infant, Premature*
  • Palivizumab
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Term Birth

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • nirsevimab
  • Palivizumab